Stocks in the United States have been mixed recently, with gains tempered by ongoing tariff uncertainties and varying corporate earnings reports. For investors willing to explore beyond the well-known names, penny stocks—often associated with smaller or newer companies—can still offer intriguing opportunities. Despite being a somewhat outdated term, these stocks remain relevant as they present potential for growth at lower price points when supported by strong balance sheets and solid fundamentals.

Top 10 Penny Stocks In The United States

Click here to see the full list of 761 stocks from our US Penny Stocks screener.

Here's a peek at a few of the choices from the screener.

QuantaSing Group

Simply Wall St Financial Health Rating: ★★★★★★

Overview: QuantaSing Group Limited offers online learning services in the People’s Republic of China and has a market capitalization of approximately $263.74 million.

Operations: The company generates its revenue of CN¥3.48 billion from operations within the People's Republic of China.

Market Cap: $263.74M

QuantaSing Group Limited, with a market cap of US$263.74 million, operates in the online learning sector in China and has shown significant profitability growth, achieving a 107.7% increase in earnings over the past year. Despite its volatile share price and inexperienced board, QuantaSing trades at a substantial discount to its estimated fair value and maintains strong financial health with no debt and ample short-term assets covering liabilities. The company reported CN¥1.54 billion in sales for the recent six months but faces forecasted earnings declines over the next three years.

• Click here and access our complete financial health analysis report to understand the dynamics of QuantaSing Group.
• Gain insights into QuantaSing Group's future direction by reviewing our growth report.

Gossamer Bio

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing seralutinib for treating pulmonary arterial hypertension in the United States, with a market cap of $203.32 million.

Operations: The company's revenue is primarily generated from its Pharmaceuticals segment, totaling $114.70 million.

Market Cap: $203.32M

Gossamer Bio, Inc., with a market cap of US$203.32 million, is focused on developing treatments for pulmonary arterial hypertension. Despite being unprofitable and not expected to achieve profitability in the next three years, Gossamer has reduced its losses by 12.8% annually over the past five years. Its short-term assets of US$309.9 million exceed both short and long-term liabilities, indicating strong financial health relative to debt obligations. Recent earnings show a net loss reduction from US$179.82 million to US$56.53 million year-over-year, while revenue reached US$114.7 million in 2024, reflecting ongoing operational progress amidst high share price volatility.

• Navigate through the intricacies of Gossamer Bio with our comprehensive balance sheet health report here.
• Assess Gossamer Bio's future earnings estimates with our detailed growth reports.

Vista Gold

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Vista Gold Corp., along with its subsidiaries, is a development-stage company focused on the gold mining industry in Australia, with a market cap of approximately $117.90 million.

Operations: Vista Gold Corp. does not report any revenue segments at this time.

Market Cap: $117.9M

Vista Gold Corp., with a market cap of approximately US$117.90 million, has transitioned to profitability, reporting a net income of US$11.25 million for 2024 compared to a net loss the previous year. The company's return on equity is outstanding at 62.8%, and it remains debt-free with stable weekly volatility. Despite being pre-revenue, Vista Gold's potential is bolstered by promising drilling results at its Mt Todd project in Australia, which could increase gold mineral reserves and enhance future prospects. The seasoned management and board further strengthen its position in the competitive mining sector.

• Unlock comprehensive insights into our analysis of Vista Gold stock in this financial health report.
• Examine Vista Gold's past performance report to understand how it has performed in prior years.

Taking Advantage

• Dive into all 761 of the US Penny Stocks we have identified here.
• Interested In Other Possibilities? The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 24 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include NasdaqGM:QSG NasdaqGS:GOSS and NYSEAM:VGZ.

This article was originally published by Simply Wall St.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com